Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c

Axovant Sciences Ltd. (NYSE: AXON) reported Q3 EPS of ($0.64), $0.49 worse than the analyst estimate of ($0.15).

Axovant Sciences also today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter

For earnings history and earnings-related data on Axovant Sciences Ltd. (AXON) click here.

You May Also Be Interested In

• Axon (AXON) Launches Draft One
• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• W.R. Berkley (WRB) Tops Q1 EPS by 13c